Commentary on ZD1839 (Iressa) in non small lung cancer

被引：3

作者：

Ranson, M ^{[1
]}

Thatcher, N ^{[1
]}

机构：

[1] Univ Manchester, Christie Hosp NHS Trust, CR UK Dept Med Oncol, Manchester M20 4BX, Lancs, England

来源：

LUNG CANCER | 2003年 / 40卷 / 01期

关键词：

D O I：

10.1016/S0169-5002(03)00041-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：77 / 78

页数：2

共 11 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2]

DOUILLARD JY, 2002, ANN ONCOL, V13, pA480

[3]

FUKUOKA M, 2002, P AN M AM SOC CLIN, V21, pA1188

[4]

GIACCONE G, 2002, ANN ONCOL, V13, pA40

[5]

JOHNSON DH, 2002, ANN ONCOL, V13, pA468

[6]

Kris MG, 2000, LUNG CANC S1, V29, P72

[7]

KRIS MG, 2002, P ASCO, V21, pA1166

[8]

M Fukuoka, 2001, P AN M AM SOC CLIN, V20

[9]

NATALE RB, 2002, P AN M AM SOC CLIN, V21, pA1167

[10]

Ranson Malcolm, 2002, Expert Rev Anticancer Ther, V2, P161, DOI 10.1586/14737140.2.2.161

← 1 2 →